<DOC>
	<DOCNO>NCT03036306</DOCNO>
	<brief_summary>The purpose study assess safety local tolerability two different concentration SCX-001 cream , compare placebo , topically applied twice day 21 day artificially induce dermal wound healthy volunteer . In addition , absorption elimination profile topically applied product determine pharmacokinetic sampling . Assessments effect SCX-001 vs. placebo do consider exploratory .</brief_summary>
	<brief_title>Dose Ranging Study Evaluate Safety Tolerability SCX-001 Cream Healthy Volunteers With Induced Dermal Incisions</brief_title>
	<detailed_description />
	<mesh_term>Nefopam</mesh_term>
	<criteria>1 . Male female volunteer age ≥18 ≤65 year voluntarily sign date Informed Consent Form ( ICF ) . 2 . Subjects , opinion Investigator , clinically acceptable result screen laboratory test specify trial protocol . 3 . Women child bear potential must provide negative pregnancy serum/urine test time screen compliant effective form birth control throughout entire study . * Nonchild bear potential mean subject history tubal ligation hysterectomy postmenopausal menses least 1 year prior enrolment study . 4 . Subjects , , opinion Investigator , able understand study , co operate study procedure willing return clinic require followup visit . 5 . Subjects must able cooperate requirement study ( e.g . able speak , read write English , expect available adverse event monitoring duration study ) . 1 . Subjects scar previous intervention evidence thermal , electrical radiation burn scar , tattoo , birthmarks mole within 5 cm treatment site . 2 . Subjects history family history keloid formation . 3 . Subjects concurrent illness condition may interfere wound heal like neoplastic , immunemediated , primary infectious disease ( e.g . carcinoma , vasculitis , connective tissue disease , immune system disorder , rheumatoid arthritis , chronic renal impairment , significant hepatic impairment , inadequately uncontrolled congestive heart failure diabetes mellitus ) clinically significant medical condition history condition may impair wound heal . 4 . Subjects skin disorder chronic currently active Investigator considers adversely affect heal acute wound involve area examine trial ( include psoriasis , dermatitis , eczema ) 5 . Subjects body mass index &lt; 15 &gt; 35 kg/m2 . 6 . A history radiotherapy study scar area . 7 . Subjects use nicotinecontaining product ( include vaping ) within one month prior screen visit . 8 . Subjects positive HIV , hepatitis B C. 9 . Subjects know sensitivity SCX001 Cream , structurally related compound constituent SCX001 Cream . 10 . Subjects know sensitivity EMLA cream , chlorhexidine adhesive dressing 11 . Subjects history malignancy five year prior screen visit . 12 . Subjects life expectancy &lt; 9 month , terminal condition factor make followup difficult ( e.g . fix address , telephone etc. ) . 13 . Subjects plan major surgical intervention course study . 14 . Subjects receive corticosteroid , immunosuppressive agent , anticoagulant , radiation therapy chemotherapy dose might interfere wound heal within last 90 day prior study enrolment . 15 . Subjects receive NSAIDS ASA past week . 16 . Subjects creatinine clearance 80 ml/min less .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>scar</keyword>
	<keyword>nefopam</keyword>
	<keyword>cicatrix</keyword>
</DOC>